3Fruchart JC,Duriez P. HDL and triglyceride as therapeutic targets[J].Curr Opin Lipdol,2002,(06):605-616.
4Plosker GL,Tavish D. Simvastatin:a reappraisal of its pharmacology and therapeutic efficacy in hyper cholesterolaemia[J].Drugs,1995,(02):334-363.
5Castelli WP. Epidemiology of coronary heart disease:the framing-ham study[J].American Journal of Medicine,1984,(04):4-6.
6Pennacchio LA,Olivier M,Hubacek JA. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing[J].Science,2001,(5540):169-173.
7van der Vliet HN,Sammels MG,Leegwater AC. Apolipoprotein A-V:a novel apolipoprotein associated with an early phase of liver regeneration[J].Biological Chemistry,2001,(48):44512-44520.
8Pennacchio LA,Rubin EM. Comparative genomic tools and databases:providing insights into the human genome[J].Journal of Clinical Investigation,2003,(08):1099-1106.
9O′Brien PJ,Alborn WE,Sloan JH. The novel apolipoprotein A5 is present in human serum,is associated with VLDL,HDL,and chylomicrons,and circulates at very low concentrations compared with other apolipoproteins[J].Clinical Chemistry,2005,(02):351-355.
10Endo K,Yanagi H,Araki J. Association found between the promoter region polymorphism in the apolipoprotein A-V gene and the serum triglyceride level in Japanese schoolchildren[J].Human Genetics,2002,(06):570-572.
